Annexin A1 inhib 
Welcome,         Profile    Billing    Logout  
 0 Companies  0 Products   0 Products   0 Diseases   0 Trials   2 News 


12345678910111213...1920»
  • ||||||||||  sirolimus / Generic mfg.
    Journal:  Annexin A1-Loaded Alginate Hydrogel Promotes Cardiac Repair via Modulation of Macrophage Phenotypes after Myocardial Infarction. (Pubmed Central) -  May 13, 2024   
    Additionally, this hydrogel led to a reduced number of pro-inflammatory macrophages and an increased proportion of pro-healing macrophages via the adenosine monophosphate (AMP)-activated protein kinase (AMPK)-mammalian target of the rapamycin (mTOR) axis...This transition mitigated early inflammatory responses and cardiac fibrosis, promoted angiogenesis, and improved cardiac function. Therefore, our study findings suggest that combining biomaterials and endogenous proteins for MI treatment is a promising approach for limiting adverse cardiac remodeling, preventing cardiac damage, and preserving the function of infarcted hearts.
  • ||||||||||  Revealing the Heterogeneity and Behavior of Pituitary Neuroendocrine Tumors in Cushing (ENDOExpo PosterArea - BCEC) -  May 5, 2024 - Abstract #ENDO2024ENDO_293;    
    CSPs can protect HK-2 cells from calcium oxalate crystal damage and effectively reduce the adhesion and aggregation of nano-COM crystals on the cell surface, which is conducive to inhibiting the formation of calcium oxalate kidney stones. Integrating spatial multi-omics-based signatures with traditional histopathological evaluation represents a promising avenue for refining the classification of pituitary tumors and holds the potential to predict patient outcomes that will ultimately guide targeted treatments in the management of PitNETs associated with CD.
  • ||||||||||  MUCH MORE THAN ANTI-DSDNA ANTIBODIES FOR LUPUS NEPHRITIS (HALL C) -  May 1, 2024 - Abstract #AUTO2024AUTO_48;    
    Furthermore, different IgG subclasses and antibodies that display cross-reactivity between DNA and other molecules may contribute to LN pathogenesis. Therefore, the use of a panel of autoantibodies is emerging as the most promising tool for the diagnosis and characterization of kidney involvement in SLE.
  • ||||||||||  IS THE OLD STATEMENT 'ONE AUTOANTIBODY/ONE DISEASE' STILL SATISFACTORY IN 2024? (HALL A) -  May 1, 2024 - Abstract #AUTO2024AUTO_9;    
    Furthermore, different IgG subclasses and antibodies that display cross-reactivity between DNA and other molecules may contribute to LN pathogenesis. Therefore, the use of a panel of autoantibodies is emerging as the most promising tool for the diagnosis and characterization of kidney involvement in SLE.
  • ||||||||||  Journal:  Bioinformatics-based analysis of potential therapeutic target genes for polycystic ovary syndrome. (Pubmed Central) -  Apr 28, 2024   
    This study represents the first application of a bioinformatics approach to identify and confirm high expression levels of RPL13, LEP, and ANXA1 in patients with Polycystic Ovary Syndrome (PCOS). These key genes-RPL13, LEP, and ANXA1-may present viable targets for therapeutic interventions in PCOS, underscoring their potential clinical importance.
  • ||||||||||  Immunophenotypic profiling reveals novel T Cell subset associated with Tolerance in pediatric transplant recipients (Exhibit Hall F1; Poster Board Number: B804) -  Apr 20, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_2413;    
    Differentially expressed genes that were specifically associated with TOT cells included ANXA1, IL7R, TCF7, THEMIS, NELL2, KLRB1 and CD40LG while Treg expressed FOXP3, IKZF2, CTLA4, IL2RA, and RTKN2, consistent with their known function in immune suppression. TCR analysis indicates unique expansions of T cell clonotypes in TOT cells not seen in Treg. Further investigation into the immunoregulatory capacity of TOT cells could be instrumental in developing new strategies to prolong graft survival.
  • ||||||||||  Review, Journal:  The role of annexins in central nervous system development and disease. (Pubmed Central) -  Apr 19, 2024   
    Annexin expression patterns vary across different CNS tumor types, providing potential prognostic markers and therapeutic targets. This review underscores the multifaceted roles of annexins in the CNS, highlighting their importance in normal functioning, disease progression, and potential therapeutic interventions.
  • ||||||||||  Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax, Vaxzevria (ChAdOx1-S recombinant) / University of Oxford, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca
    Journal:  Comparative single-cell transcriptomic profile of hybrid immunity induced by adenovirus vector-based COVID-19 vaccines. (Pubmed Central) -  Apr 19, 2024   
    This review underscores the multifaceted roles of annexins in the CNS, highlighting their importance in normal functioning, disease progression, and potential therapeutic interventions. In this study, antibody response and a single-cell RNA-seq analysis were conducted on peripheral blood mononuclear cells from five different groups: na
  • ||||||||||  Immunophenotypic Profiling Reveals Novel T Cell Subset Associated with "tolerance" in Pediatric Transplant Recipients () -  Apr 16, 2024 - Abstract #FOCIS2024FOCIS_255;    
    Differentially expressed genes that were specifically associated with TOT cells included ANXA1, IL7R, TCF7, THEMIS, NELL2, KLRB1 and CD40LG while Treg expressed FOXP3, IKZF2, CTLA4, IL2RA, and RTKN2, consistent with their known function in immune suppression. TCR analysis indicates unique expansions of T cell clonotypes in TOT cells not seen in Treg. Further investigation into the immunoregulatory capacity of TOT cells could be instrumental in developing new strategies for enhancing graft survival.
  • ||||||||||  Biomarker, Review, Journal, Tumor microenvironment:  The role of ANXA1 in the tumor microenvironment. (Pubmed Central) -  Apr 10, 2024   
    This article describes the role of ANXA1 in the various components of the tumor microenvironment and its mechanism of action, as well as the existing clinical treatment measures related to ANXA1. These findings provide insight for the further design of strategies targeting ANXA1 for the diagnosis and treatment of malignant tumors.
  • ||||||||||  Biomarker, Journal:  Serum biomarkers in patients with drug-resistant epilepsy: a proteomics-based analysis. (Pubmed Central) -  Apr 8, 2024   
    The up-regulated proteins mainly include UGGT2, PDIA4, SEMG1, KIAA1191, CCT7 etc. and the down-regulated proteins mainly include ROR1, NIF3L1, ITIH4, CFP, COL11A2 etc. Pathway enrichment analysis identified that the upregulated proteins were mainly enriched in processes such as immune response, extracellular exosome, serine-type endopeptidase activity and complement and coagulation cascades, and the down-regulated proteins were enriched in signal transduction, extracellular exosome, zinc/calcium ion binding and metabolic pathways. PPI network analysis revealed that the core proteins nodes include PRDX6, CAT, PRDX2, SOD1, PARK7, GSR, TXN, ANXA1, HINT1, and S100A8 etc. The discovery of these differential proteins enriched our understanding of serum biomarkers in patients with DRE and potentially provides guidance for future targeted therapy.
  • ||||||||||  Biomarker, Review, Journal, Tumor microenvironment:  An overview of the regulatory role of annexin A1 in the tumor microenvironment and its prospective clinical application (Review). (Pubmed Central) -  Mar 26, 2024   
    The present review explored the important role of ANXA1 in regulating the cell?specific crosstalk between various compartments of the TME and analyzed the guiding significance of the crosstalk effects in promotion or suppressing cancer progression in the development of cancer treatments. The literature shows that ANXA1 is critical for the regulation of the TME, indicating that ANXA1 signaling between cancer cells and the TME is a potential therapeutic target for the development of novel therapeutic approaches for impeding cancer development.
  • ||||||||||  Journal:  The structural properties of full-length annexin A11. (Pubmed Central) -  Mar 22, 2024   
    We show that the peptides have a remarkable character typical of a native helix and that mutations do not alter the behaviour suggesting that they are required for interactions rather than being structurally important. Our work paves the way to a more thorough understanding of the ANXA11 functions.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Identification of Annexin A1 as a novel driver of lenvatinib resistance in hepatocellular carcinoma (Section 26) -  Mar 5, 2024 - Abstract #AACR2024AACR_5376;    
    Based on this observation, we further demonstrated the in vitro role of secretory ANXA1 in LenR HCC cells in inducing macrophage polarization towards the M2 phenotype. In conclusion, ANXA1 may regulate lenvatinib resistance intrinsically via the promotion of cancer stemness and extrinsically via the induction of an immunosuppressive TME.
  • ||||||||||  Azvudine : An emerging immunomodulator in the treatment of cancer and viral infections (Section 47) -  Mar 5, 2024 - Abstract #AACR2024AACR_5112;    
    Typically, nucleoside analog drugs function by integrating into DNA and impeding DNA synthesis, evident in drugs like 5-FU, Capecitabine, Ara-C, and Gemcitabine...Given these revelations, there's a compelling argument that FNC monotherapy possesses immense potential as an anti-tumor agent. The potent anticancer effects of FNC in vitro and in vivo warrants further investigation of its anticancer potential as immunomodulator.
  • ||||||||||  Heterogeneity of the hormone receptor-positive breast tumor immune microenvironment according to patient's body mass index (Section 9) -  Mar 5, 2024 - Abstract #AACR2024AACR_4691;    
    Our current data suggested that obesity was associated with multi-directional changes in the immune activities, possibly implying an unresolved inflammation in the HR+ BC tissue. Further investigation incorporating other cell types and their interaction with immune cells in both tumor and matched normal mammary tissues is warranted and on-going, which could provide more understanding of HR+ breast TIME and lead to speculation on therapeutic implications.
  • ||||||||||  sorafenib / Generic mfg.
    Association of stem cell-like phenotype with isoform specific functions of AKTs in hepatocytes (Section 14) -  Mar 5, 2024 - Abstract #AACR2024AACR_4276;    
    AKT1 loss correlated with an enhanced stem cell-like phenotype, including increased migration towards a chemoattractant, higher resistance to chemotherapy, and enhanced ability to form spheres. These results contribute to the understanding of the role of AKT isoforms in regulating stemness in liver cancer and may serve as a basis for investigation into isoform specific inhibitors.
  • ||||||||||  MDX-124 / Medannex
    Preclinical, Journal:  A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo. (Pubmed Central) -  Feb 19, 2024   
    Furthermore, MDX-124 significantly inhibited tumour growth in both the 4T1-luc triple-negative breast and Pan02 pancreatic cancer syngeneic mouse models (p?<?0.0001). These findings suggest ANXA1-targeted therapy is a viable and innovative approach to treat tumours which overexpress ANXA1.
  • ||||||||||  Journal:  Identification of Hypoxia Prognostic Signature in Glioblastoma Multiforme Based on Bulk and Single-Cell RNA-Seq. (Pubmed Central) -  Feb 10, 2024   
    Overall, our study highlights the potential of a hypoxia-related prognostic signature as a valuable resource for forecasting the survival outcome of GBM patients. The multi-omics approach integrating bulk sequencing, single-cell analysis, and immune microenvironment assessment enhances our understanding of the intricate biology characterizing GBM, thereby potentially informing the tailored design of therapeutic interventions.